Century Therapeutics Appoints Han Lee, Ph.D., M.B.A., And Martin Murphy, Ph.D., To Board To Advance iPSC-Derived Cell Therapy Pipeline

Century Therapeutics, Inc., a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, has announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. Dr. Lee will serve on the Audit and Compensation Committees, while Dr. Murphy will join the Compensation and Nominating and Corporate Governance Committees.

Brent Pfeiffenberger, Pharm.D., CEO of Century Therapeutics, welcomed the new board members, emphasizing their strategic importance as the company advances its pipeline of iPSC-derived cell therapies. He noted that Century is focused on delivering its innovative programs, including CNTY-813, a potentially curative, off-the-shelf investigational therapy for type 1 diabetes. Pfeiffenberger highlighted that Dr. Lee and Dr. Murphy bring complementary expertise in capital formation, corporate development, life science investment, and strategic oversight, which will help the company accelerate clinical development and create value for patients and stakeholders.

Dr. Han Lee most recently served as President and Chief Financial Officer of ImmPACT Bio, Inc., a private clinical-stage biotech company that was acquired by Lyell Immunopharma in 2024. He previously held CFO positions at Neogene Therapeutics, Inc. and Arcellx, Inc., and earlier in his career, worked in corporate development and ventures at AstraZeneca plc. Dr. Lee earned a Ph.D. in genetics and an M.B.A. from Yale University, and holds a B.A. in molecular cell biology with a genetics emphasis, as well as a minor in chemistry from the University of California, Berkeley.

Dr. Martin Murphy brings extensive experience in life science investment and company creation. He currently serves on the boards of several organizations, including Synairgen plc, Cora Biosciences Limited, and Legal & General UK Universities Ventures LP. Previously, he co-founded Syncona Limited and served as CEO and investment committee chair of Syncona Investment Management Limited. Dr. Murphy also held senior roles at MVM Life Science Partners LLP, 3i Group plc, and McKinsey & Company. 

He holds a Ph.D. from the University of Cambridge and an M.A. in biochemistry from the University of Oxford. With these appointments, Century Therapeutics strengthens its leadership team as it continues to advance its iPSC-derived cell therapy programs toward clinical development and aims to deliver meaningful treatments for patients with high-impact diseases.